Literature DB >> 22257082

Exanthematous drug eruption due to valsartan.

Gunseli Ozturk1, Bengu Gerceker Turk, Bircan Senturk, Meltem Turkmen, Gulsen Kandiloglu.   

Abstract

OBJECTIVE: Valsartan is an angiotensin II receptor blocker (ARB) used for treatment of hypertension. The well-known adverse effects of valsartan are dizziness, headache and cough. Valsartan-related cutaneous side effects have been reported previously in a limited number of case reports.
MATERIALS AND METHODS: A 47-year-old man admitted with diffuse, itchy erythematous maculopapular eruption all over the body. He has been taking 160 mg valsartan daily for 10 days before onset of the eruption. On the third day of valsartan therapy, erythema had appeared over the face and spread throughout the whole body within a week. Histopathologic examination of the lesions showed lymphocyte exocytosis, spongiosis, necrotic keratinocytes in the epidermis, and mixed inflammatory cell infiltrates including perivascular eosinophils in the dermis. The patient was diagnosed as drug reaction due to valsartan with historical, clinical and histopathologic features. DISCUSSION AND
CONCLUSION: Most common antihypertensive agents including diuretics, beta blockers, calcium-channel blockers, angiotensin-converting enzyme inhibitors have many cutaneous side effects. However, there are a few reports about the cutaneous side effects of ARBs. Physicians should be aware of the cutaneous side effects of this commonly used agent and valsartan should be considered as a triggering factor of an exanthematous drug reactions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257082     DOI: 10.3109/15569527.2011.647179

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  3 in total

1.  Severe acute interstitial nephritis induced by valsartan: A case report.

Authors:  Tong Chen; Peng-Cheng Xu; Shui-Yi Hu; Tie-Kun Yan; Jian-Qing Jiang; Jun-Ya Jia; Li Wei; Wen-Ya Shang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

2.  Late-Onset Rash from Irbesartan: An Immunological Reaction.

Authors:  Bárbara Kong Cardoso; Marta Martins; Sofia Martins Farinha; Regina Viseu; Elza Tomaz; Filipe Inácio
Journal:  Eur J Case Rep Intern Med       Date:  2019-06-19

3.  Olmesartan: induced maculopapular rash.

Authors:  Aruna Bhushan; S T Ved Bhushan
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.